10x Genomics (TXG) Tops Q3 EPS by 7c

10x Genomics (NASDAQ: TXG) reported Q3 EPS of ($0.37), $0.07 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $131.1 million versus the consensus estimate of $129.35 million.

GUIDANCE:

10x Genomics sees FY2022 revenue of $500-520 million, versus the consensus of $509.87 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth